PTC Therapeutics
PTCT
157 hedge funds and large institutions have $1.91B invested in PTC Therapeutics in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 21 closing their positions.
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
30% more capital invested
Capital invested by funds: $1.47B → $1.91B (+$446M)
19% more funds holding
Funds holding: 132 → 157 (+25)
0% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 51
20% less call options, than puts
Call options by funds: $29M | Put options by funds: $36.4M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
Top Sellers
PTCT Hedge Fund Activity: Q1 2015 in Review
157 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2015, worth a combined $1.91B — up 30% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PTCT positions and 21 closed out — a net gain of 25 holders — while 51 added to existing stakes and 51 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $98.4M. The largest seller was Granahan Investment Management, cutting an estimated $46.6M.
- 157 institutional investors held PTC Therapeutics (PTCT) as of Q1 2015, up from 132 in Q4 2014.
- Funds reported $1.91B of PTC Therapeutics stock for Q1 2015, up 30% quarter-over-quarter.
- 46 funds opened new PTC Therapeutics positions in Q1 2015 and 21 closed out, a net change of +25 holders.
- The largest PTC Therapeutics buyer in Q1 2015 was Westfield Capital Management, an estimated $98.4M added.
- The largest PTC Therapeutics seller in Q1 2015 was Granahan Investment Management, an estimated $46.6M sold.
Based on aggregated 13F filings for Q1 2015.